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Abstract
Background: While the treatment of HER2 over-expressing breast cancer with recent HER-targeted drugs has been
highly effective for some patients, primary (also known as innate) or acquired resistance limits the success of these
drugs. microRNAs have potential as diagnostic, prognostic and predictive biomarkers, as well as replacement
therapies. Here we investigated the role of microRNA-630 (miR-630) in breast cancer progression and as a predictive
biomarker for response to HER-targeting drugs, ultimately yielding potential as a therapeutic approach to add value
to these drugs.
Methods: We investigated the levels of intra- and extracellular miR-630 in cells and conditioned media from breast
cancer cell lines with either innate- or acquired- resistance to HER-targeting lapatinib and neratinib, compared to
their corresponding drug sensitive cell lines, using qPCR. To support the role of miR-630 in breast cancer, we
examined the clinical relevance of this miRNA in breast cancer tumours versus matched peritumours. Transfection
of miR-630 mimics and inhibitors was used to manipulate the expression of miR-630 to assess effects on response
to HER-targeting drugs (lapatinib, neratinib and afatinib). Other phenotypic changes associated with cellular
aggressiveness were evaluated by motility, invasion and anoikis assays. TargetScan prediction software, qPCR,
immunoblotting and ELISAs, were used to assess miR-630’s regulation of mRNA, proteins and their phosphorylated forms.
Results: We established that introducing miR-630 into cells with innate- or acquired- resistance to HER-drugs
significantly restored the efficacy of lapatinib, neratinib and afatinib; through a mechanism which we have
determined to, at least partly, involve miR-630’s regulation of IGF1R. Conversely, we demonstrated that blocking
miR-630 induced resistance/insensitivity to these drugs. Cellular motility, invasion, and anoikis were also observed
as significantly altered by miR-630 manipulation, whereby introducing miR-630 into cells reduced cellular
aggression while inhibition of miR-630 induced a more aggressive cellular phenotype.
Conclusions: Taken together, our findings suggest miR-630 as a key regulator of cancer cell progression in HER2
over-expressing breast cancer, through targeting of IGF1R. This study supports miR-630 as a diagnostic and a
predictive biomarker for response to HER-targeted drugs and indicates that the therapeutic addition of miR-630
may enhance and improve patients’ response to HER-targeting drugs.
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Approximately a quarter of all breast cancers are associated
with the HER2-overexpression [1]. Amplification of the
HER2 gene has been associated with more aggressive
disease and, prior to the development of HER-targeted
therapies, had an overall poor prognosis [2]. Since the
initial development of trastuzumab (Herceptin); the use
of lapatinib (Tykerb) a small-molecule tyrosine kinase
inhibitor (TKI) that dually targets human epidermal
growth factor receptor 2 (HER2) and epidermal growth
factor receptor (EGFR/HER1)) have vastly improved
clinical benefit in recent years [3,4]. Unfortunately, evi-
dence of innate- or acquired- resistance to these drugs
[5-8] indicates that, despite their initial success in the
treatment of HER2-overexpressing cancers, their use
in the clinic is becoming somewhat compromised. Newer
HER-targeting drugs including neratinib (HK1-272) and
afatinib (BIBW 2992), both of which are irreversible oral
small molecule TKIs of target HER2, EGFR/HER1 and
HER4, are producing promising results in clinical trials
[9,10]. Unfortunately, it is probable that these drugs will
eventually be faced with similar problems due to resist-
ance as that of their predecessors.
There is an urgent need to identify predictive biomarkers
for HER-targeting drugs in order to improve patients’strati-
fication and, subsequently, patients’ outcome. microRNAs
(miRNAs) are small (approximately 18–25 nucleotides long)
non-protein coding RNAs that have been associated with
regulating gene transcription at a post-translational level
[11]. In general, miRNAs are considered as negative reg-
ulators of gene expression. For example, miRNAs acting
as tumour suppressors are responsible for controlling the
levels of genes promoting tumourigenesis and are often
decreased in cancerous compared to normal cells [12].
miR-630 has previously been reported to regulate
cisplatin-induced cell death in both non-small cell
lung cancer and head and neck cancer [13,14]. In a
separate study, inhibition of miR-630 in lung cancer
cells was found to be associated with an induction of
cellular migration and invasion [15]. Furthermore, the
over expression of miR-630 has recently been implicated in
degradation of Insulin Growth Factor Receptor 1 (IGF1R)
mRNA and protein levels and subsequent enhanced apop-
tosis in pancreatic cancer cells [16].
In this study, we aimed to investigate the relevance of
miR-630 in breast cancer and its potential to regulate
response to HER-targeting agents and cancer cell aggres-
sion. Through initial analysis of our innately and acquired
drug-resistant cell lines we identified miR-630 as being
significantly decreased compared to drug-sensitive age-
matched parent cells. The relevance of further studying
this target was confirmed by the finding that miR-630 was
significantly decreased in breast cancer tissue compared
to matched peritumour tissue. Our subsequent studies
suggest that manipulation of miR-630 can influence cell
response to HER-targeted agents, lapatinib, neratinib and
afatinib apparently via its regulation of IGF1R. Motility, in-
vasion and anoikis assays indicate that miR-630 may also
play part in regulating the metastatic phenotype of HER2
over-expressing breast cancer cells.
Methods
Cell culture and treatments
SKBR3 and HCC1954 cells, obtained from ATCC, were
cultured in RPMI-1640 (Sigma-Aldrich) with 10% FCS
(PAA) and 1% L-glutamine (Sigma-Aldrich). MDA-MB-
453 were cultured in McCoys 5A with 10% FCS and 1% L-
glutamine (Sigma-Aldrich). Lapatinib-resistant SKBR3 and
HCC1954 cells (SKBR3-LR and HCC1954-LR, respectively)
were established by continuously exposing cells to lapatinib,
starting with 5 nM and increased stepwise to 250 nM over
6 months. Similarly, neratinib-resistant cells (HCC1954-NR)
were established by continuously exposing cells to neratinib,
increasing stepwise to 250 nM for over 4 months. Age-
matched parent cells (SKBR3-Ag, HCC1954-Ag) were
maintained in culture, in parallel, but were not exposed to
drug. Lapatinib, neratinib and afatinib were obtained from
Sequoia Research Chemicals Ltd. (Pangbourne UK).
RNA isolation from conditioned medium
For analysis of extracellular miR-630 levels, conditioned
medium (CM) was collected, centrifuged and filtered, as
we have previously described [17].
miR-630 analysis in cells & conditioned medium
Total RNA was isolated from cell lines and CM using
TriReagent (Sigma-Aldrich). cDNA was prepared from
10 ng cell-derived and 4 μlC M - d e r i v e dt o t a lR N A ,
respectively, as we described previously [18]. miR-630
(001563, ABI, UK) was quantified using the cycle threshold
(CT) adjusting to the levels of U6 snRNA (001973, ABI,
UK) used as an endogenous control.
Assessment of miR-630 expression in patient derived
tumour tissue
miR-630 expression in breast cancer [all breast tissue
(n=56) and HER2+ breast tissue (n=6)] was determined
based on previous miRNA profiling of breast tumours and
matched peritumours using a publically available data
s e t( G S E 4 0 5 2 5 )o nG e n eE xpression Omnibus (GEO)
(http://www.ncbi.nlm.nih.gov/geo/) [19]. microRNA ex-
pression levels, p-values and Log fold change (Log FC)
between experimental conditions were determined using
the GEO2R analysis function.
microRNA inhibition/mimic manipulation in cells
SKBR3-Ag and HCC1954-Ag cells were transfected with
miR-630 inhibitor (Cat #4464084, ID: MH11552, ABI, UK)
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were used at a final concentration of 30 nM and transfected
using lipofectamine 2000 (Invitrogen). 48-72 hrs post-
transfection cells harvested for RNA and protein and
functional assays were performed. Similarly, SKBR3-LR,
HCC1954-LR and MDA-MB-453 cells were transfected
with miR-630 mimic (Cat #4464066, ID MH11552, ABI,
UK) or miRNA mimic negative control (Cat #4464058).
Assessing effects of miR-630-regulated cellular response
to HER-targeting drugs
Following transfection with miR-630 inhibitor, miR-630
mimic or their relevant negative controls, cells were ex-
posed to their approximate IC50 concentrations of lapatinib
(as indicated Tables 1 and 2) previously been determined
by ourselves and/or others [20-23]. Fixed concentrations of
neratinib and afatinib were also used (see Tables 1 and 2).
Following 72 hrs incubation with the given drug, cell prolif-
eration was assessed using acid phosphatase analysis.
qPCR for IGF1R
Total RNA was isolated from cell lines using TriReagent
(Sigma-Aldrich). cDNA was prepared from 1 μgt o t a lR N A .
IGF1R (Hs99999020_m1, ABI, UK) was quantified using
the threshold cycle (CT) adjusting to the levels of β-actin
(4352933E, ABI, UK), established as not differing signifi-
cantly in expression levels between cell populations being
assessed and so suitable as endogenous control.
Immunoblotting
Total protein (30-100 μg) were resolved on 7.5% SDS-PAGE
and transferred to PVDF membranes (Bio-Rad Laboratories).
The following primary antibodies were used: HER2
(Calbiochem); EGFR, IGF1Rβ (Cell Signalling Technology);
β-actin (Sigma-Aldrich). Following incubation in the ap-
propriate horseradish peroxidase-conjugated secondary
antibodies (Cell Signalling Technology), the immunoblots
were developed using chemiluminescence (Thermo Fisher)
and detected on a Chemidoc exposure system (Bio-Rad
Laboratories). Densitometry was performed on the bands
of protein expression using NIH ImageJ software and nor-
malised to the loading control (β-actin).
Enzyme-linked immunosorbent assays (ELISAs)
ELISAs (R&D Systems) for p-IGF1R, p-HER2 and p-EGFR
were used according to the manufacturer’si n s t r u c t i o n s .A s
recommended, concentrations of total protein used for the
ELISAs were prepared as 700 μg/ml (for p-IGFR) and
20 μg/ml (for p-HER2 and p-EGFR), with 100 μlo fe a c h
loaded per ELISA well. Thus, 70 μg/well of total protein
was loaded for the p-IGFR ELISA and 2 μg/well of total
protein was loaded for the p-HER2 and p-EGFR ELISAs.
Cell motility –assessed using wound healing assays
Transfected cells (3 × 10
5 cells/well for SKBR3 cell line
variants and 2 ×10
5/well for HCC1954 cell line variants)
were seeded on 24-well plates and cultured for 24 hrs to
confluency. Monolayers were scratched with a pipette tip
and the resulting wounded areas were monitored as previ-
ously described [24]. Throughout the duration of monitor-
ing wound closure, cells were maintained in low serum
(1%) containing medium to reduce any influences due to
proliferation.
Cell migration and invasion –assessed using transwell inserts
Migration and invasion assays were performed and quanti-
fied as previously described [24]. Transfected cells (HCC1954
variants, 5×10
4/insert; SKBR3-Ag, 1×10
6/insert; SKBR3-LR,
5×10
5/insert) were seeded in the upper compartment and
allowed to migrate for 48 hrs (HCC1954 variants) and 72 hrs
(SKBR3 variants), respectively. Cells were seeded in low
serum (1%) containing medium in the upper chamber and
10% serum-containing medium in the well below the insert.
Anoikis assay
Transfected cells (1×10
4 cells/well) were seeded onto a
24-well plates coated with Poly(hydroxyethyl methacrylic)
acid (Sigma-Aldrich) or 95% ethanol and were cultured
f o r4 8h r s .A l a m a rb l u ed y e( 1 0 0μl; Serotec, UK) was
added/well and absorbance read at 570 nm; reference
wavelength, 600 nm.
Statistical and bioinformatics analysis
Online miRNA target prediction software (TargetScan
Human Release 6.2) was used to identify proteins potentially
regulated by miR-630. Statistical analysis was performed in
Table 1 Inhibition of miR-630 reduces sensitivity to HER-targeted drugs, lapatinib, neratinib and afatinib
Drug Drug Conc. Cell line % Cell -proliferation
drug+NC Inhibitor
% Cell proliferation
drug+miR-630 Inhibitor
% Resistance induced
by miR-630 inhibitor p-value
Lapatinib 0.05 μM SKBR3-Ag 50.0±9.6 63.6± 9.1 13.6± 0.8 0.002
Lapatinib 0.7 μM HCC1954-Ag 40.8±3.6 63.7± 4.8 22.9± 6.7 0.039
Neratinib 0.005 μM SKBR3-Ag 34.7±6.4 43.2± 7.4 8.6± 1.6 0.017
Neratinib 0.005 μM HCC1954-Ag 43.2±2.3 58.2± 2.4 15.1± 3.0 0.019
Afatinib 0.005 μM SKBR3-Ag 47.7±5.2 62.3± 4.6 14.6± 1.7 0.002
Afatinib 0.005 μM HCC1954-Ag 70.4±8.3 82.1± 9.0 11.7± 2.3 0.019
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with p <0.05 considered as statistically significant. GraphPad
Prism 5.0 was used for graph generation (Graph Pad
Software Inc, La Jolla, USA).
Results
Changes in both intracellular and extracellular miR-630
levels are associated with acquired-resistance to
HER-targeting drugs
miRNA profiling of parent (drug sensitive) and lapatinib-
resistant cell lines, using TaqMan low density arrays, iden-
tified miR-630 as differentially expressed. The differential
expression of miR-630 was validated using qPCR, whereby
miR-630 was found to be significantly decreased in
HCC1954-LR (Figure 1A (i); p <0.001) and SKBR3-LR
(Figure 1A (ii); p <0.01) cells compared to their corre-
sponding age-matched parent cells. Similarly, miR-630 ex-
pression was significantly decreased in neratinib-resistant
HCC1954-NR (Figure 1A (iii); p <0.01). There was also a
slight, but unsubstantial (1.25 fold) decrease of miR-630
in trastuzumab-resistant SKBR3 cells (not shown). To
investigate whether miR-630 may be associated with
innate resistance, in addition to acquired resistance, we
next determined its levels in innately-resistant MDA-MB-
453 cells [22]. Here a significant decrease in miR-630 was
demonstrated when compared to innately-sensitive SKBR3
cells (Figure 1A (iv), p <0.05). Interestingly, the extracellular
levels of miR-630 in the corresponding CM also reflected
that of the acquired-resistant cells i.e. HCC1954-LR,
SKBR3-LR and HCC1954-NR (Figure 1B (i-iii), p <0.001),
with a trend towards a decrease in MDA-MB-453 com-
pared to SKBR3 CM (Figure 1B (iv), p =0.07).
miR-630 is decreased in tumour compared to peritumour
breast cancer tissues
In order to assess the possible clinical importance of miR-
630 and so relevance to further study this microRNA, using
a publically available dataset (GSE40525) we investigated
the expression of miR-630 in breast cancer tumour tis-
sues versus matched peritumour tissues. A significant
decrease in miR-630 expression in all breast cancer tu-
mours compared to matched peritumours was observed
(Log FC: 1.83; p <0.001) (Figure 2A). Subsequent analysis of
those breast tissues that were HER2+ also displayed a sig-
nificant decrease in miR-630 in HER2+ tumours compared
to matched peritumour tissue (Log FC: 2.02, p <0.05)
(Figure 2B).
miR-630 regulates cellular response to HER-targeted drugs
miR-630 inhibition (when compared to the negative
control inhibitor) caused significant increase in resistance/
insensitivity to the anti-proliferative affects of each of
lapatinib, neratinib and afatinib (Table 1). To ensure that an
unbiased functional assessment of miR-630 was performed,
we also transfected acquired-resistant cell lines (SKBR3-LR
and HCC1954-LR) with miR-630 mimic. In terms of cellu-
lar response to the HER-targeted drugs assessed, miR-630
mimic was found to further enhance the anti- proliferative
effects of all drugs assessed in HCC1954-LR and SKBR3-
LR as well as innately-resistant MDA-MB-453 (Table 2).
Phenotypic changes in HER2-overexpressing cells including
motility, invasion and resistance to anoikis are also
regulated, at least in part, by miR-630
We also observed that inhibition of miR-630 in HCC1954-
Ag and SKBR3-Ag, compared to their respective negative
controls, was associated with increased motility as evalu-
ated via wound-healing assays (Figure 3A (i) p <0.05 & (ii)
p <0.05 - after 72 hrs); increased migration through trans-
wells (Figure 3B (i) p <0.05 & (ii) p <0.05); increased in-
vasion through extracellular matrix-coated transwells
(Figure 3C (i) p <0.01 & (ii) p <0.05); and resistance to
anoikis (Figure 3D (i) p <0.05 & (ii) p <0.05). Conversely,
miR-630 mimic transfection in HCC1954-LR and SKBR3-
LR cells was associated with opposite effects i.e. decreased
cellular motility (Figure 4A (ii) p <0.001 and (ii) p <0.05);
Table 2 Over-expression of miR-630 restores sensitivity to lapatinib, neratinib and afatinib in cells with either
acquired- or innate resistance to HER-targeting drugs
Drug Drug Conc. Cell line Drug+ NC
mimic
Drug+miR-630
mimic
% Anti-proliferative benefit
with miR-630 mimic
p-value
Lapatinib 3 μM SKBR3-LR 82.5±1.4 69.5±1.2 12.9± 1.4 0.011
Lapatinib 5 μM HCC1954-LR 27.6±6.3 17.8±4.5 9.7± 2.3 0.026
Lapatinib 6 μM MDA-MB-453 19.0±0.9 9.9±0.9 9.1± 1.6 0.015
Neratinib 0.5 μM SKBR3-LR 63.3±1.9 56.3±1.2 7.0± 1.0 0.019
Neratinib 0.5 μM HCC1954-LR 26.3±4.6 22.3±4.7 3.9± 0.1 0.000
Neratinib 0.5 μM MDA-MB-453 45.3±7.5 28.3±3.0 17.0± 4.9 0.037
Afatinib 0.5 μM SKBR3-LR 78.4±1.5 70.4±0.7 8.4± 1.4 0.031
Afatinib 0.5 μM HCC1954-LR 30.5±7.0 20.7±6.5 9.8± 0.5 0.001
Afatinib 0.5 μM MDA-MB-453 50.6±8.3 31.4±10.4 19.2± 2.3 0.007
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decreased invasion (Figure 4C (i) p <0.05 & (ii) p <0.05);
and increased sensitivity to cell death by anoikis (Figure 4D
(i) p <0.01 and (ii) p <0.01).
Proposed mechanism of action
Through the use of target prediction software (TargetScan-
Human Release 6.2), IGF1R was predicted to be regulated
by miR-630. Initially we assessed the levels of IGF1R in
our acquired lapatinib-resistant cells (HCC1954-LR and
SKBR3-LR) and found a significant increase of this protein
compared to the corresponding parent cells (Figure 5A
(i)). We also observed that IGF1R to be increased in our
neratinib-resistant cells (HCC1954-NR) compared to its
corresponding parent cells (not shown).
Subsequently we demonstrate that when miR-630 is
inhibited, and thus drug resistance and increased cell
aggression is induced, expression levels of IGF1R protein
are significantly increased in both HCC1954-Ag (p <0.05)
and SKBR3-Ag (p <0.01) (Figure 5A (ii)). Similarly,
conferred cellular sensitivity to the HER-targeting drugs
and the reduction of cell aggression, that we observed by
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Figure 1 miR-630 expression decreases with both acquired- and innate resistance. (A) miR-630 expression was significantly decreased in
cells with acquired lapatinib resistance ((i) HCC1954-LR and (ii) SKBR3-LR) and acquired neratinib-resistance ((iii) HCC1954-NR) compared to their
age-matched control cells (HCC1954-Ag, SKBR3-Ag). miR-630 expression was also significantly decreased in cells with innate resistance to lapatinib
((iv) MDA-MB-453) compared to cells with innate sensitivity (SKBR3). (B) Extracellular expression of miR-630 was also assessed in the corresponding
conditioned medium of these cells and trends followed that of the cells. All results represent biological repeats n=3±SEM, where *p <0.05,
**p <0.01,* * * p <0.001.
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Figure 2 Clinical relevance of miR-630 in breast cancer. Using a publically available data set (GSE40525) from Gene Expression Omnibus
(GEO) the expression of miR-630 was determined in breast cancer tumour tissues compared to matched peritumour tissue. (A) miR-630 was
significantly decreased in all breast tumours (n= 56) and also in (B) HER2+ breast cancer tissue (n= 6) compared to matched peritumours.
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Figure 3 Inhibition of miR-630 increased cell motility, migration, invasion and resistance to anoikis. Following transfection with miR-630
inhibitor or a negative control (NC) inhibitor in (i) HCC1954-Ag and (ii) SKBR3-Ag (A) motility, assessed by wound-healing assay (B) migration,
through transwells; (C) invasion, through ECM-coated transwells; and (D) anoikis, on poly(hydroxyethyl methacrylic) acid coated plates; were
found to be significantly changed as a consequence of miR-630 inhibition. Results represent n=3± SEM, where *p <0.05,* * p <0.01.
Corcoran et al. Molecular Cancer 2014, 13:71 Page 6 of 12
http://www.molecular-cancer.com/content/13/1/71miR-630 mimic, was coupled with a significant reduction of
IGF1R in HCC1954-LR (p <0.05) and SKBR3-LR (p <0.05)
(Figure 5A (iii)).
To investigate if miR-630 acts by regulating mRNA
transcription, the levels of IGF1R post-transfection with
either the miR-630 inhibitor or miR-630 mimic were
assessed by qPCR. Here we found that although a trend
towards an increase in IGF1R mRNA existed following
miR-630 inhibition compared to the negative control
(Additional file 1: Figure S2), this did not reach statistical
significance. Similarly, there was no significant decrease in
IGF1R mRNA levels following miR-630 mimic transfection
when compared to the levels in cells transfected with the
negative control mimic (Additional file 1: Figure S2).
As HER2 and EGFR are the targets for all 3 drugs
assessed, we also determined the protein levels of these
specific targets using immunoblotting. Increased levels
of HER2 and EGFR were observed in our acquired
lapatinib-resistant cells (HCC1954-LR and SKBR3-LR)
compared to the corresponding parent cells (Figure 5A (i)).
Inhibition of miR-630 in HCC1954-Ag and SKBR3-Ag was
associated with increased levels of HER2 and EGFR protein
(Figure 5A (ii)). Conversely, miR-630 mimic transfec-
tion in HCC1954-LR and SKBR3-LR cells was associated
with decreased levels of HER2 and EGFR expression
(Figure 5A (iii)). All corresponding densitometry for im-
munoblots can be found in Additional file 2: Figure S1.
Next, we investigated if miR-630’s regulation of IGF1R
and subsequent effects on HER2 and EGFR may be associ-
ated with altered phosphorylation states of some (or all) of
these proteins. We observed that inhibition of miR-630 in
SKBR3-Ag and HCC1954-Ag cells induced a significant in-
crease (or in some cases tending towards significance) in
pIGF1R, pHER2 and pEGFR (Figure 5B (i)). Conversely,
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Figure 4 Over-expression of miR-630 in lapatinib resistant cells decreases cell motility, migration, invasion and anoikis. Following
transfection with miR-630 mimic or a negative control (NC) mimic in HCC1954-LR (i) and SKBR3-LR (ii) (A) motility, assessed by wound-healing assay;
(B) migration, through transwells; (C) invasion, through ECM-coated transwells; (D) anoikis, on Poly(hydroxyethyl methacrylic) acid coated plates; were
found to be significantly altered as a consequence of miR-630 induced expression. Results represent n=3±SEM, where *p< 0 . 0 5 ,* * p <0.01, ***p<0.001.
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phorylation of all three proteins assessed (Figure 5B (ii)).
Discussion
Limited studies to date have reported on the role of miR-
630 in cancer. Specifically, reports using the lung cancer cell
line, A549, identified miR-630 as a regulator of cisplatin-
induced cell death, with over-expression of miR-630 indu-
cing chemoprotective properties [13]. Conversely, the au-
thors of that study also identified that miR-630 failed to
protect cells when treated with C2-CER, CdCl2, etoposide,
mitoxantrone, and oxaliplatin and in some cases induced
chemo-sensitivity [13]. In head and neck squamous cell
carcinoma, also reporting on cisplatin-induced cell death,
Huang et al. [14] reported that induced expression of miR-
630 with cisplatin treatment of HNSCC cells dramatically
decreased cell survival. Induced miR-630 expression de-
creased levels of anti-apoptotic genes, BCL2 and BCL2L2
whereas inhibition of miR-630 in HNSCC cells up-regulated
these genes and was associated with increased cell survival
[14]. The over expression of miR-630 in the pancreatic
cancer cell line PANC-1 has recently been associated
with decreased mRNA and protein levels of IGF1R as
well as enhanced apoptosis [16] while the motility and in-
vasion of the ANGPTL1 over-expressing lung cancer cell
line (CL1-5/ANGPTL1) has been shown to be restored
A  (i)
β-Actin
EGFR
HER2
IGF1R
HCC1954-Ag
-NC    –630
SKBR3-Ag
-NC   –630
*** *
P=0.08
P=0.06 * **
*
P=0.06
P=0.08
*
**
P=0.06
IGF1R
HCC1954-LR
+NC +630
SKBR3-LR
+NC +630
(iii)
HER2
β-Actin
EGFR
B (i)
(ii)
IGF1R
β-Actin
HCC1954 SKBR3
-Ag     –LR -Ag –LR
HER2
EGFR
(ii)
Figure 5 miR-630’s mechanism of action. IGF1R was predicted as a direct target of miR-630. (A) (i) Initially the expression of IGF1R, HER2 and
EGFR was assessed in our acquired lapatinib-resistant cells (HCC1954-LR and SKBR3-LR) and was found to be increased compared to levels in their
age-matched parent cells. (ii) Inhibition of miR-630 induced an increase in IGF1R, HER2 and EGFR expression in both HCC1954-Ag and SKBR3-Ag
cells compared to levels in the negative control transfected cells. (iii) Conversely, induced expression of miR-630 in lapatinib-resistant HCC1954-LR
and SKBR3-LR cells caused a decrease in IGF1R, HER2 and EGFR levels. (B) The phosphorylated forms of IGF1R, HER2 and EGFR were assessed using
ELISAs, indicating that (i) inhibition of miR-630 induced an increase in pIGF1R, pHER2 and pEGFR, while (ii) over-expression of miR-630 decreased the
pIGF1R, pHER2 and pEGFR levels. Representative immunoblots of n=3 biological repeats. n=3±SEM, where *p< 0 . 0 5 ,* * p <0.01, ***p<0.001.
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http://www.molecular-cancer.com/content/13/1/71following miR-630 inhibition [15]. To the best of our know-
ledge, prior to our studies, miR-630 has never been associ-
ated with any subtype of breast cancer, with response/
resistance to HER-targeted drugs and/or breast cancer cell
aggression. Here we observed that miR-630 is associated
with –and may be causally involved in– regulating resist-
ance to HER-targeting drugs. Initially using our cell line
models of acquired lapatinib-resistance (HCC1954-LR,
SKBR3-LR) and neratinib-resistance (HCC1954-NR) and
subsequently cells with innate resistance (MDA-MB-453),
we observed a decrease in miR-630 expression.
The pursuit of extracellular predictive biomarkers offers
potential for minimising invasive procedures such as tissue
biopsies in the clinic. Previously, we have reported the ex-
istence of RNAs circulating extracellularly in serum/plasma
from cancer patients [25]. We have also reported on the
detection of circulating miRNAs [11,26,27]. In this study,
we identified that medium conditioned by both lapatinib-
and neratinib- resistant cell line variants of HCC1954 and
SKBR3 cells (i.e. HCC1954-LR, SKBR3-LR, HCC1954-NR)
demonstrated a significant decrease of miR-630 levels com-
pared to conditioned medium from age-matched parent
cells (HCC1954-Ag, SKBR3-Ag), correlating with the obser-
vation in the corresponding cell lines. Conditioned medium
from MDA-MB-453 cells also showed a decrease to some
extent in miR-630 levels compared to that in SKBR3 cells.
This suggests relevance for miR-630 as an extracellular i.e.
minimally-invasive predictive biomarker; a novel observa-
tion that warrants further investigation in future studies.
To support our in vitro findings, and so indicate the
relevance of choosing miR-630 for further functional
evaluation, our subsequent analysis was to determine
the clinical relevance of miR-630. Evidently, miR-630
was decreased in breast cancer tumours compared to
peritumour tissues which was also apparent when
assessed in specifically HER2-overexpressing tumours.
Having established that reduced miR-630 expression
levels are associated with both innate- and acquired-
resistance, we progressed next to establishing if this
was specific to lapatinib and neratinib alone or more
generally associated with HER-targeting drugs. For this
purpose, we also included afatinib in our analyses. Through
inhibition of miR-630 (in sensitive parent cells) or its
over-expression (in acquired lapatinib-resistant or innately-
resistant cells) our studies identified a correlation between
miR-630 expression and cellular response to all 3 HER-
targeting drugs tested i.e. lapatinib, neratinib and afatinib.
To more comprehensively evaluate a functional relevance
of miR-630 in HER2-overexpressing breast cancer we next
investigated whether miR-630 may confer other phenotypic
influences. Interestingly we observed that inhibition of
miR-630, in sensitive parent SKBR3 and HCC1954 cells,
was also associated with increased cell motility, migration,
invasion and resistance to anoikis. On the contrary, miR-
630 mimic transfection in acquired-resistant SKBR3-LR
and HCC1954-LR cells resulted in a substantial block on
these phenotypic changes. In agreement with our observa-
tions, increased cell migration and invasion have widely
been reported to be associated with drug resistance
[ 2 8 - 3 0 ] .A d d i t i o n a l l y ,w eh a v ep r e v i o u s l yr e p o r t e dt h a t
drug resistance can also be coupled with increased resist-
ance to anoikis [24]. Our findings in relation to miR-630’s
involvement in regulating cell motility and invasion are
supported by the recent study by Kou et al. [15] demon-
strating that lung cancer cells (CL1-5) overexpressing
ANGTL1 have reduced motile and invasive capabilities
with increased levels of miR-630; whereas increased
migration/invasion induced by shANGPTL1 in CL1-0
cells was associated with decreased miR-630 expression
[15]. The authors of this study also demonstrated that
inhibition of miR-630 in CL1-5/ANGTL1 cells restored
invasion and migration [15]. Most breast cancers are of
epithelial cells. Epithelial cells typically are attached to a
basement membrane, rather than existing in suspension.
For such cells to survive in suspension, as required for cir-
culating tumour cells to be transported in the bloodstream
or lymphatics and progress to forming tumour metastasis
at secondary sites, these cells must evade a form of apop-
tosis termed anoikis [31]. In addition to invasion and
migration, the ability of cells to resist anoikis and have
anchorage-independent growth is a key contributing factor
in cancer cell metastasis. Our observation that miR-630
may also regulate anoikis-resistance in breast cancer cells
further indicates the potential importance of this miRNA in
modulating overall breast cancer cell aggression.
Investigating the mechanism(s) by which miR-630
could be conferring these influences on sensitivity/
resistance as well as altered cell aggression, IGF1R
(which our bioinformatics analysis predicted as a target
of miR-630) was found to be a directly influenced by
miR-630 manipulation. Interestingly, elevated IGF1R
expression, observed in our acquired lapatinib resistant
cells (SKBR3-LR and HCC1954-LR) compared to their
age-matched parent cells was inversely correlated with
decreased miR-630 expression in the same resistant cells.
Advancing on this observation, we demonstrate that
inhibition of miR-630 -resulting in increased resistance
and metastatic phenotype in SKBR3 and HCC1954- was
associated with increased IGF1R expression in both cell
lines. Interestingly, in the presence of the miR-630 mimic,
that induced an increase in sensitivity to HER-targeting
drugs for acquired-resistant SKBR3-LR and HCC1954-LR
cells as well as decreased cell aggressiveness, a reduction
of IGF1R expression was observed. These findings corres-
pond with that of several other reports that correlate
IGF1R expression with resistance to HER-targeting drugs
and other chemotherapy [32-36]. Furthermore, increased
IGF1R has also been previously attributed with an
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h o w e v e r ,a r et h ef i r s ti nb r e a s tc a n c e rt od e t e r m i n et h a tt h e
mechanism involved is, at least partly, regulated by aberrant
miR-630 expression. This observation is supported by the
recent study by Farhana et al. [16] who demonstrate that
miR-630 pairs to a 7 nucleotide conserved region located in
position 2658–2665 of IGF1R 3’- U T Ra n ds h o w e dt h a t
overexpression of miR-630 reduced the mRNA and protein
levels of IGF1R in the pancreatic cancer cell line, PANC-1
[16]. IGF1R mRNA was found not to be significantly al-
tered following miR-630 manipulation; thus we propose
that the predominant mechanism of action for miR-630 in
breast cancer cells is likely to be at a post-transcriptional
level by its inhibition of IGF1R protein translation. Follow-
ing on from this observation, we subsequently investigated
if post-translational modifications may be influenced by
miR-630. Here we observed that inhibition of miR-630
increased IGF1R phosphorylation, while introduction of
miR-630 induced its de-phosphorylation.
The drugs included in this study target both HER2 and
EGFR. For this reason we also investigated whether miR-
630 may modulate the expression of these receptors. We
initially observed that the acquired lapatinib resistant cells
used for this study (SKBR3-LR and HCC1954-LR) have
increased levels of both HER2 and EGFR compared to
their age-matched parent controls. This is supported by
previous studies identifying that increased levels of HER2
or EGFR correlate with resistance to trastuzumab and other
chemotherapy [32,40]. In addition to this, we observed that
miR-630 inhibition induced an increase in both HER2 and
EGFR, whereas over-expression of miR-630 decreased these
proteins. Previous studies have indicated that crosstalk be-
tween IGF1R and other tyrosine kinases such as HER2 and
EGFR can drive cancer progression and drug resistance
[41-43]. In keeping with these previous studies, our findings
suggest that miR-630 directly regulates IGF1R which, sub-
sequently, leads to alterations in HER2 and EGFR poten-
tially driving the phenotypic affects demonstrated in this
study. Interestingly, we also found that, with altered phos-
phorylation of IGF1R following miR-630 manipulation, the
phosphorylated levels of HER2 and EGFR also change. This
further supports the potential of an associated cross-talk
between IGF1R and these HER-family receptors following
the phosphorylation of IGF1R. This suggested interaction
between IGF1R and/or HER family receptors associated
with miR-630 manipulation warrants further investigation.
A model for our proposed mechanism for miR-630 is illus-
trated in Figure 6.
IGF1R
miR-630
Inhibition of 
miR-630 in 
drug-sensitive 
cell
HER2
EGFR
Drug-sensitivity
Motility/Invasion
Anoikis
B
IGF1R
miR-630
HER2
EGFR Introduction of 
miR-630 into  
drug-resistant 
cell
Drug-sensitivity
Motility/Invasion
Anoikis
A IGF1R
1 2
3
1
2
3
Figure 6 Proposed model for manipulation of miR-630 in breast cancer cells. Elevated IGF1R, HER2 and EGFR have been associated with
drug resistance and cancer cell aggression. (A) Introducing miR-630 into acquired or innately resistant breast cancer cells can (1) directly inhibit
the mRNA translation of IGF1R. (2) Crosstalk of IGF1R to other receptor tyrosine kinases (HER2 and EGFR) can lead to their subsequent down
regulation and so (3) cause cells to become more sensitive to HER-targeting agents as well as decreasing their aggressive phenotype (in terms of
motility, invasion and resistance to anoikis). (B) Conversely, inhibiting the expression of miR-630 in sensitive breast cancer cells can (1) prevent its
binding to and translational suppression of target mRNA IGF1R. This causes an increase in IGF1R protein expression which in turn can (2) induce
elevated HER2 and EGFR expression and as a result, (3) cells exhibit a more aggressive phenotype.
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In conclusion, our study indicates for the first time that
miR-630 plays an important role in modulating response
to HER-targeting drugs, as well as in overall aggressive
phenotypic characteristics of HER2-overexpressing breast
cancer cells. We have demonstrated that miR-630 may
serve as a predictive biomarker for response to treatment
in HER2-overexpressing breast cancer; with early indica-
tions from our conditioned media studies of its relevance
as a minimally-invasive (as well as cell-based) biomarker.
Our functional studies provide evidence that introducing
miR-630 therapeutically in combination with HER-targeted
drugs can help to circumvent resistance/insensitivity
and reduce cancer cell aggression, thus improving overall
response and so adding value to this class of drugs; through
a mechanism that we unravelled as its controlling of IGF1R
at a post-transcriptional level. Preclinical in vivo assess-
ments of miR-630 as a predictive biomarker and thera-
peutic are now warranted.
Additional files
Additional file 1: Figure S2. IGF1R mRNA levels following miR-630
manipulation. (A) The levels of IGF1R mRNA following miR-630 inhibition
were not significantly increased in (i) HCC1954-Ag or (ii) SKBR3-Ag cells
compared to the negative control transfected cells. Similarly, transfection
of miR-630 mimic into resistant (i) HCC1954-LR or (ii) SKBR3-LR cells did
not induce a significant decrease in IGF1R mRNA compared the levels in
cells transfected with the negative control mimic.
Additional file 2: Figure S1. Densitometry for immunoblotting.
Densitometry to accompany immunoblots illustrated in Figure 5. (A)
Expression of (i) IGF1R (ii) HER2 and (iii) EGFR was found to be elevated
in the acquired lapatinib-resistant cell lines (HCC1954-LR and SKBR3-LR)
compared to the age-matched parent controls (HCC1954-Ag and SKBR3-Ag).
(B) Inhibition of miR-630 induced an increase in (i) IGF1R (ii) HER2 and (iii)
EGFR expression in HCC1954-Ag and SKBR3-Ag cells. (C) Introduction of
miR-630 mimic induced a decrease in (i) IGF1R (ii) HER2 and (iii) EGFR in
HCC1954-LR and SKBR3-LR cells. Results represent n =3± SEM, where
*p< 0 . 0 5 ,* * p< 0 . 0 1 ,* * * p <0.001.
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